Local Field Potentials Predict Motor Performance in Deep Brain Stimulation for Parkinson's Disease
Background Deep brain stimulation (DBS) is an effective treatment option for patients with Parkinson's disease (PD). However, clinical programming remains challenging with segmented electrodes. Objective Using novel sensing‐enabled neurostimulators, we investigated local field potentials (LFPs)...
Saved in:
Published in | Movement disorders Vol. 38; no. 12; pp. 2185 - 2196 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.12.2023
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Deep brain stimulation (DBS) is an effective treatment option for patients with Parkinson's disease (PD). However, clinical programming remains challenging with segmented electrodes.
Objective
Using novel sensing‐enabled neurostimulators, we investigated local field potentials (LFPs) and their modulation by DBS to assess whether electrophysiological biomarkers may facilitate clinical programming in chronically implanted patients.
Methods
Sixteen patients (31 hemispheres) with PD implanted with segmented electrodes in the subthalamic nucleus and a sensing‐enabled neurostimulator were included in this study. Recordings were conducted 3 months after DBS surgery following overnight withdrawal of dopaminergic medication. LFPs were acquired while stimulation was turned OFF and during a monopolar review of both directional and ring contacts. Directional beta power and stimulation‐induced beta power suppression were computed. Motor performance, as assessed by a pronation‐supination task, clinical programming and electrode placement were correlated to directional beta power and stimulation‐induced beta power suppression.
Results
Better motor performance was associated with stronger beta power suppression at higher stimulation amplitudes. Across directional contacts, differences in directional beta power and the extent of stimulation‐induced beta power suppression predicted motor performance. However, within individual hemispheres, beta power suppression was superior to directional beta power in selecting the contact with the best motor performance. Contacts clinically activated for chronic stimulation were associated with stronger beta power suppression than non‐activated contacts.
Conclusions
Our results suggest that stimulation‐induced β power suppression is superior to directional β power in selecting the clinically most effective contact. In sum, electrophysiological biomarkers may guide programming of directional DBS systems in PD patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
---|---|
Bibliography: | J.R. has received speaker honoraria from Medtronic. G.‐H. S. has received speaker honoraria from Medtronic and Boston Scientific. A. S. has served on adivsory boards of Abbott, Medtronic and Zambon, has received speaker honoraria from Abbott, Boston Scientific, Abbvie, Alexion and Novartis, consulting honoraria from Abbott and Medtronic, honoraria for expert testimony from Abbott and travel support from Abbott, Boston Scientific, Abbvie, Alexion and Novartis. P. K. is a member of advisory boards for AbbVie and Stadapharm. A. A. K. has served on advisory boards of Medtronic and has received honoraria and travel support from Medtronic, Boston Scientific, Ipsen Pharma and Teva. All other authors declare no conflict of interest. Relevant conflicts of interest/financial disclosures Funding agencies Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Project‐ID 424778381 – TRR 295. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy – EXC‐2049 – 390688087 (Project Neurocure – BrainLab). Lundbeck Foundation "Adaptive and precise targeting of cortex‐basal ganglia circuits in Parkinson's Disease” (R336‐2020‐1035). Berlin Institute of Health Junior Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH). Johannes L. Busch and Jonathan Kaplan contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0885-3185 1531-8257 |
DOI: | 10.1002/mds.29626 |